Dr. Savitha Balaraman, MD

Dr. Balaraman practices at Corewell Health Farmington Hills Hospital in Farmington Hills, Michigan, part of Corewell Health.

Dr. Balaraman's NPI, 1083696694, was assigned on November 18, 2005. Dr. Balaraman holds Michigan license 4301072119.

Dr. Balaraman's primary practice is Corewell Health Farmington Hills Hospital, at 28050 Grand River Avenue, Farmington Hills, MI 48336 in Oakland County. The practice phone is (248) 471-8000.

Dr. Balaraman's primary practice is Corewell Health Farmington Hills Hospital in Farmington Hills, Michigan, part of Corewell Health. Dr. Balaraman is also affiliated with Corewell Health William Beaumont University Hospital. The medical group on file is Beaumont Medical Group - Specialty Services. Dmand AI also links Dr. Balaraman to 3 more hospitals, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Balaraman practices, 6 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Balaraman's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Balaraman is licensed in Michigan.

CMS data shows 139,001 Medicare services from Dr. Balaraman across 56 procedure codes in 2024, for 691 Medicare patients. Medicare paid $1,308,262 for them.

CMS counts 691 Medicare patients who saw Dr. Balaraman in 2024. The largest group is 65 to 74, with 293 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 19% are also on Medicaid. Their average risk score is 2.26, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Balaraman's median patient age at 68, with 69% women.

In 2024, Dr. Balaraman wrote 2,445 Medicare Part D claims for 513 patients. 78% of them were for generic drugs. CMS names the drug for 2,060 of them, across 45 drugs with 11 or more claims each, at $4,726,102 in total drug cost. In 2023, CMS named 1,694 claims across 42 drugs.

Dr. Balaraman accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Balaraman as offering telehealth.

Dmand AI links 10 papers to Dr. Balaraman, published from 2011 to 2023. 2022 was the busiest year, with 3. The most frequent topics are Prostatic Neoplasms and Genetic Testing. Dr. Balaraman has published most often in Urol Pract. Dr. Balaraman's most frequent co-authors are Siddharth Ramanathan, Andrew Stephen Korman, MD and Adil Jamal Akhtar, MD.

Dmand AI links Dr. Balaraman to 4 clinical trials, 2 of them phase 2 studies. Conditions studied include Bulbo-Spinal Atrophy, X-Linked, Carcinoma, Non-Small-Cell Lung and Lymphoma, Follicular.

CMS Open Payments shows 288 general payments to Dr. Balaraman from 41 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 47% of the total. Merck Sharp & Dohme Corporation paid the most, $3,055.